XML 124 R103.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Selected Quarterly Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Jan. 01, 2017 | Oct. 02, 2016 | Jul. 03, 2016 | Apr. 03, 2016 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Sales to customers | $ 20,195 | $ 19,650 | $ 18,839 | $ 17,766 | $ 18,106 | $ 17,820 | $ 18,482 | $ 17,482 | $ 76,450 | $ 71,890 | $ 70,074
Gross profit | 12,952 | 12,748 | 13,016 | 12,380 | 12,572 | 12,334 | 13,146 | 12,153 | 51,096 | 50,205 | 48,538
Earnings before provision for taxes on income | 2,560 | 4,790 | 4,748 | 5,575 | 4,324 | 5,281 | 4,904 | 5,294 | 17,673 | 19,803 | 19,196
Net earnings | $ (10,713) | $ 3,764 | $ 3,827 | $ 4,422 | $ 3,814 | $ 4,272 | $ 3,997 | $ 4,457 | $ 1,300 | $ 16,540 | $ 15,409
Basic net earnings per share | $ (3.99) | $ 1.40 | $ 1.42 | $ 1.63 | $ 1.41 | $ 1.56 | $ 1.46 | $ 1.62 | $ 0.48 | $ 6.04 | $ 5.56
Diluted net earnings per share | $ (3.99) | $ 1.37 | $ 1.40 | $ 1.61 | $ 1.38 | $ 1.53 | $ 1.43 | $ 1.59 | $ 0.47 | $ 5.93 | $ 5.48
Restructuring charge, after tax | $ 237 | $ 136 | $ 101 | $ 121 | $ 251 | $ 76 | $ 97 | $ 120 |  |  |
Litigation income (expense) net after-tax | (506) | (97) | (352) |  | (80) | (46) | (493) | (56) |  |  |
Litigation expense | 645 | 118 | 493 |  | 96 | 55 | 600 | 66 |  |  | $ 141
Acquisition related costs after tax | 313 |  |  |  |  |  |  |  |  |  |
Acquisition related costs | 217 |  |  |  |  |  |  |  |  |  |
Restructuring charges |  |  |  |  |  |  |  |  | $ 309 | $ 491 | 509
In-process research and development, after tax | 266 |  |  |  |  |  |  |  |  |  |
In-process research and development | 408 |  |  |  |  |  |  |  | 408 | 29 | 224
Asset impairment benefit | 116 |  |  |  |  |  |  |  |  |  |
Provisional charge | 13,600 |  |  |  |  |  |  |  |  |  |
asset impairment charge after-tax |  |  | 125 |  |  |  |  |  |  |  |
Asset Impairment Charges |  |  |  |  |  |  |  |  | 795 | 283 | 624
Medical Devices |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Litigation expense |  |  |  |  |  |  |  |  | 1,139 | 806 | 5
Restructuring charges | 284 | 187 | 128 | 161 | 298 | 109 | 141 | 137 | 850 | 685 | 590
In-process research and development |  |  |  |  |  |  |  |  |  |  | 10
Asset Impairment Charges |  |  | 182 |  |  |  |  |  | 215 |  | 346
Consumer |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Sales to customers | 3,540 | 3,356 | 3,478 | 3,228 | 3,432 | 3,261 | 3,419 | 3,195 |  |  |
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Sales to customers | 9,681 | 9,695 | 8,635 | 8,245 | 8,232 | 8,400 | 8,654 | 8,178 |  |  |
Litigation expense |  |  |  |  |  |  |  |  | 117 |  | 136
In-process research and development |  |  |  |  |  |  |  |  | 396 | $ 29 | $ 214
Med Devices |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Sales to customers | $ 6,974 | 6,599 | 6,726 | 6,293 | $ 6,442 | $ 6,159 | $ 6,409 | $ 6,109 |  |  |
AMO |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs after tax |  |  |  | 251 |  |  |  |  |  |  |
Acquisition related costs |  |  |  | $ 38 |  |  |  |  |  |  |
AMO | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  | 140 |  |
Actelion |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs after tax |  | 255 | 199 |  |  |  |  |  |  |  |
Acquisition related costs |  | $ 367 | $ 213 |  |  |  |  |  | 800 |  |
Actelion | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Summary of Selected Quarterly Financial Data (unaudited) |  |  |  |  |  |  |  |  |  |  |
Acquisition related costs |  |  |  |  |  |  |  |  | $ 797 |  |

X
- Definition After Tax Restructuring Charge + References No definition available. + Details
Name: | jnj_AfterTaxRestructuringCharge
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Asset Impairment Charges (Benefit) + References No definition available. + Details
Name: | jnj_AssetImpairmentChargesBenefit
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition asset impairment charge after-tax + References No definition available. + Details
Name: | jnj_Assetimpairmentchargeaftertax
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Combination, Acquisition Related Costs, After-tax + References No definition available. + Details
Name: | jnj_BusinessCombinationAcquisitionRelatedCostsAftertax
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Litigation Income (Expense) Net After Tax. + References No definition available. + Details
Name: | jnj_LitigationIncomeExpenseNetAfterTax
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Provisional Income Tax Expense (Benefit) + References No definition available. + Details
Name: | jnj_ProvisionalIncomeTaxExpenseBenefit
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research And Development In Process, after Tax + References No definition available. + Details
Name: | jnj_ResearchAndDevelopmentInProcessafterTax
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details
Name: | us-gaap_EarningsPerShareBasic
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details
Name: | us-gaap_EarningsPerShareDiluted
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_GrossProfit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SalesRevenueGoodsNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesAndDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AMOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |